Breviscapine suppresses the growth and metastasis of prostate cancer through regulating PAQR4-mediated PI3K/Akt pathway - 30/05/20
, Mingquan Gao b , Xinwu Guo a , Henan Zhang c, ⁎ , Fuchun Jiang d, ⁎, 1 Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 7 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | PAQR4 is highly expressed in prostate cancer and associated with poor survival outcome. |
• | PAQR4-silenced inhibits proliferation and metastasis of prostate cancer cells. |
• | Breviscapine treatment suppresses cancer cell proliferation and metastasis. |
• | Breviscapine exerts antitumor effects by blocking PAQR4/PI3K/Akt pathway in prostate cancer. |
Abstract |
Objectives |
Prostate cancer, one of the most frequently diagnosed tumors of men, leads to poor quality of life. Previous studies have shown that breviscapine (BRE) exerts therapeutic activity in malignant tumors. However, the role and mechanism of BRE exhibit an anti-tumor effect on prostate cancer are largely unknown.
Methods |
The mRNA and protein levels in prostate cancer tissues and cell lines were measured using RT-qPCR, western blot, and immunohistochemical staining, respectively. Cell proliferation, invasion, and migration in both PC3 and DU145 cells were evaluated using CCK-8 and Transwell assay. The effect of BRE on cell proliferation and metastasis by regulating the PAQR4-mediated PI3K/Akt pathway in vitro and in vivo was determined.
Results |
PAQR4 was significantly overexpressed in prostate cancer tissues and cell lines, which was positively correlated with poor prognosis. Knockdown of PAQR4 inhibited the proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT) of both PC3 and DU145 cells. Mechanistically, BRE treatment significantly suppressed the malignant biological behavior of both prostate cancer cells by downregulating PAQR4 and blocking the PI3K/Akt pathway. In vivo experiments, BRE administration remarkably inhibited tumor growth and metastasis in a xenograft model of prostate cancer.
Conclusion |
Our findings revealed that BRE exerts anti-tumor and anti-metastasis roles in prostate cancer by inhibiting PAQR4-mediated PI3K/Akt pathway, which provides a new therapeutic agent for prostate cancer clinical treatment.
Le texte complet de cet article est disponible en PDF.Abbreviations : BRE, CCK-8, EMT, LY, PAQR4, RT-qPCR
Keywords : Prostate cancer, Breviscapine, PAQR4, PI3K/Akt pathway, Proliferation, Metastasis
Plan
Vol 127
Article 110223- juillet 2020 Retour au numéro
Article précédent
- Dexmedetomidine pretreatment protects the heart against apoptosis in ischemia/reperfusion injury in diabetic rats by activating PI3K/Akt signaling in vivo and in vitro
- Jian-Hua Chang, Mei-Mei Jin, Jun-Tian Liu
- H2S donor GYY4137 ameliorates paclitaxel-induced neuropathic pain in mice
- Bedoor Qabazard, Willias Masocha, Maitham Khajah, Oludotun Adebayo Phillips
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?